# Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Source: https://onco.cc/trials/nct05760378/  
OnCo record `nct05760378` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of camrelizumab, capecitabine, eribulin and carboplatin in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. is a phase 3, randomised interventional study registered as NCT05760378 by Fudan University, with a registry enrolment figure of 223 participants, started 2023-03-17 and due to reach its primary completion in 2025-01-01. Interventions recorded: Famitinib; Camrelizumab; nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05760378
- Phase: 3
- Setting: An Open, Randomized Phase III Study of Famitinib With Camrelizumab Plus Treatment of Physician's Choice (TPC) Versus Camrelizumab Plus TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic Triple-negative Breast Cancer
- Sponsor: Fudan University
- Enrolled: 223

## Sources

- ClinicalTrials.gov NCT05760378: https://clinicaltrials.gov/study/NCT05760378

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Eribulin](https://onco.cc/drugs/eribulin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05760378.json